Clinical evaluation and management of acute severe colitis

Blomberg, Björn

doi:10.1002/ibd.3780060309

Cited by 7 publications

(5 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a review article, data from 20 uncontrolled studies of 185 patients treated with cyclosporine indicated an initial response, measured by avoidance of colectomy, of 68% and sustained response of 42% (11). Similar results of 66% initial and 45% sustained response rates were reported in a more recent review (12). The two most recent studies reported 236 patients, of whom 83% experienced initial response and 58% of whom had a sustained response (13,14).…”

Section: Discussionsupporting

confidence: 88%

Infliximab in Pediatric Ulcerative Colitis: Two‐year Follow‐up

Mamula,

Markowitz,

Cohen

et al. 2004

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

ObjectivesThe role of infliximab in treating pediatric ulcerative colitis (UC) is not defined. The authors previously have described their experience with the open label use of infliximab in nine children with moderate to severe UC. The aim of this study was to describe the outcome of these patients after a minimum 2‐year follow‐up and to describe the responses of eight additional patients to this medication.MethodsThe authors reviewed all pediatric patients with UC who received infliximab at The Children's Hospital of Philadelphia from its first use until February 2003. Tolerance of the infusions and adverse events were recorded.ResultsFollow‐up information for a minimum of 2 years was reviewed for the nine initial patients. A total of 73 infliximab infusions were administered to these patients. Seven of nine (78%) patients were considered to be responders to the initial dose of infliximab. Two of these patients became nonresponders within 9 months of the first dose of infliximab and underwent colectomy. Of the remaining five (56%) patients with sustained response, two continue to receive infliximab infusions and three are doing well without infliximab. One patient experienced an infusion reaction, and one experienced herpes zoster infection. We have treated eight additional UC patients with infliximab. Seven (88%) patients were considered responders. One responder experienced relapse within 2 months. Overall, a short‐term improvement was seen in 14 of 17 (82%) patients, and sustained improvement in 10 of 16 (63%) patients followed up for more than 9 months. All five patients with severe or fulminant UC, unresponsive to 2 weeks of intravenous corticosteroid therapy, experienced improvement with infliximab. Infliximab was well tolerated.ConclusionInfliximab is associated with short‐ and long‐term clinical improvement in children and adolescents with moderate to severe UC.

show abstract

Section: Discussionsupporting

confidence: 88%

Infliximab in Pediatric Ulcerative Colitis: Two‐year Follow‐up

Mamula,

Markowitz,

Cohen

et al. 2004

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

“…[59][60][61][62] However, cases of moderate-to-severe infection without any effect on the IBD course have been reported. 64 From the clinical and endoscopic point of view, the non-IBD colitis and the IBD colitis caused by Aeromonas can be indistinguishable. 64 From the clinical and endoscopic point of view, the non-IBD colitis and the IBD colitis caused by Aeromonas can be indistinguishable.…”

mentioning

confidence: 99%

Aeromonas Species

Lobatón

Hoffman

Vermeire

et al. 2015

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…Approximately 50% of patients refractory to the first 10 days of intensive therapy do not have severe mucosal colitis on colonoscopy and may safely undergo an additional 5-10 days of therapy prior to considering a surgical alternative (104,106). The widespread use of endoscopy has not been adopted because of fear of increasing or initiating colonic distension or frank perforation during the procedure.…”

Section: Outcome Of Severe Colitis: Predictive Factorsmentioning

confidence: 99%

“…Bloomberg and Jarnerot (106) reported a series of 34 adult patients with severe colitis who did not respond to 10 days of intensive medical therapy. Twelve of 17 given continued treatment did well with a longer treatment regimen and stayed healthy during a five year follow‐up.…”

Section: Complications Of Severe Ucmentioning

confidence: 99%